The Food and Drug Administration (FDA) announced that Desferal (deferoxamine mesylate for injection; Novartis) 2g vials are being discontinued as of September 2015. The reason for the discontinuation has not been disclosed.

Desferal is an iron chelating agent indicated for use in acute iron intoxication and chronic iron overload due to multiple transfusions. Desferal chelates iron by forming a stable complex that prevents the iron from entering into further chemical reactions. It readily chelates iron from ferritin and hemosiderin but not readily from transferrin; it does not combine with the iron from cytochromes and hemoglobin.

RELATED: USPSTF Revisits Evidence on Iron Screening, Supplementation in Pregnancy

Desferal 500mg vials (NDC 0078-0467-91) will continue to be sold in 4-count cartons.

For more information call (888) 463-6332 or visit